ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0314 • ACR Convergence 2021

    PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome

    Dana DiRenzo1, Susan Robinson2, Clifton Bingham1, Alan Baer3 and Thomas Grader-Beck1, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Sjogren’s Syndrome (SS) is a systemic autoimmune disease that has considerable impact on health-related quality of life (HRQL). The European League Against Rheumatism (EULAR)…
  • Abstract Number: 0313 • ACR Convergence 2021

    Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease?

    Katja Perdan Pirkmajer1, Matija TOMSIC1 and Alojzija Hocevar2, 1University Medical Centre Ljubljana, Ljubljana, Slovenia, 2UKC Ljubjana, Ljubjana, Slovenia

    Background/Purpose: Ultrasonographically depicted morphological changes of major salivary glands (SG) have been recently correlated with the disease activity in primary Sjögren’s (pSS)1. The aim of…
  • Abstract Number: 0312 • ACR Convergence 2021

    Prognostic Value of Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome

    Francesco Ferro1, Gianmaria Governato1, Giovanni Fulvio1, Gaetano La Rocca1, Silvia Fonzetti1, Giacomo Aringhieri2, Valentina Donati3, Marta Mosca4 and Chiara Baldini5, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2University of Pisa, 3Diagnostic and Interventional Radiology, Department of Translational Research and of New Technologies in Medicine and Surgery, Pisa, Italy, 3AOUP, Unit of Pathological Anatomy, Pisa, Italy, 4Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 5University of Pisa, Pisa, Italy

    Background/Purpose: In the last decade, salivary gland ultrasonography (SGUS) has appeared as a useful tool for the diagnosis of primary Sjögren’s syndrome (pSS) and for…
  • Abstract Number: 0307 • ACR Convergence 2021

    Cerebellar Ataxia in Primary Sjogren’s Syndrome, Is Gluten Sensitivity the Answer?

    Fu Chuen Kon1, Mohammed Akil2, Rachael Kilding2, Kar-Ping Kuet2, Priya Shanmugarajah3, Nigel Hoggard4 and Marios Hadjivassiliou3, 1Department of Rheumatology, Sheffield Teaching Hospitals NHS Trust, Sheffield, 2Department of Rheumatology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom, 3Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust and University of Sheffield, Royal Hallamshire Hospital, Sheffield United Kingdom, Sheffield, United Kingdom, 4Academic Unit of Radiology, Royal Hallamshire Hospital, Sheffield, United Kingdom

    Background/Purpose: Cerebellar ataxia is an uncommon neurological complication of Primary Sjogren’s Syndrome (PSS), with case reports being the highest level of evidence available. The underlying…
  • Abstract Number: 0318 • ACR Convergence 2021

    Correlation Between Prognostic Nutritional Index and Primary Sjögren’s Syndrome Disease Activity

    Kbra Kalkan1, Ufuk Ilgen2, Zeliha Ademoğlu3 and Hakan Emmungil3, 1trakya uviversity, istanbul, Turkey, 2Trakya University Medical School, Department of Rheumatology, Edirne, Turkey, 3Trakya University, Edirne, Turkey

    Background/Purpose: Since primary Sjögren’s Syndrome (pSS) is a very heterogeneous disease with systemic manifestations, factors influencing the outcome of patients with pSS need to be…
  • Abstract Number: 0317 • ACR Convergence 2021

    Patient and Physician Perspectives on EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): A Qualitative Interview Study

    Samantha Wratten1, Carl Cooper2, Jessica Flynn2, Natasha Griffiths2, Rebecca Hall3, Linda Abetz-Webb2, Simon J Bowman4, Wolfgang Hueber5, Briana Ndife6 and Pushpendra Goswami5, 1Adelphi Values, Macclesfield, United Kingdom, 2Adelphi Values, Bollington, United Kingdom, 3Adelphi Values Ltd, Bollington, United Kingdom, 4Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis, East Hanover, NJ

    Background/Purpose: The aim of this research was to gain qualitative patient and physician feedback on the EULAR Sjögren’s syndrome patient reported index (ESSPRI) and the…
  • Abstract Number: 0315 • ACR Convergence 2021

    Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change

    Samantha Wratten1, Natasha Griffiths2, Carl Cooper2, Jessica Flynn2, Rebecca Hall3, Linda Abetz-Webb2, Wolfgang Hueber4, Briana Ndife5 and Pushpendra Goswami4, 1Adelphi Values, Macclesfield, United Kingdom, 2Adelphi Values, Bollington, United Kingdom, 3Adelphi Values Ltd, Bollington, United Kingdom, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis, East Hanover, NJ

    Background/Purpose: The aim of this study was to gain qualitative patient feedback on the appropriateness of two Patient Reported Outcome (PRO) measures as assessments of…
  • Abstract Number: 0319 • ACR Convergence 2021

    Assessment of EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains in Routine Clinical Practice in an Integrated Delivery Network in the United States

    Briana Ndife1, Irina Pivneva2, Carmine Rossi2 and James Signorovitch3, 1Novartis, East Hanover, NJ, 2Analysis Group, Inc., Montréal, QC, Canada, 3Analysis Group, Inc., Boston, MA

    Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disease associated with diverse phenotypes, which may include systemic disease activity. In real-world practice, the clinical presentation…
  • Abstract Number: 0321 • ACR Convergence 2021

    Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation

    André van Maurik1, David Gardner2, Saba Nayar2, Charlotte Smith2, Kenneth Clark1, Prafull Mistry1, Rajesh Punwaney3, David Roth3, Robert Henderson1, Xavier Mariette4 and Francesca Barone2, 1GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 2University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…
  • Abstract Number: 0320 • ACR Convergence 2021

    Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome

    Liseth de Wolff1, Suzanne Arends2, Elena Pontarini3, Michele Bombardieri3, Simon J Bowman4 and Hendrika Bootsma2, 1University Medical Centre Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands, 3Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, 4Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: Recent randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to show clinical efficacy.1-3 Several RCTs used the EULAR Sjögren’s Syndrome Disease Activity…
  • Abstract Number: 0316 • ACR Convergence 2021

    Exploring Alternative Responder Definitions for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) for Use in Sjögren’s Clinical Trials

    Samantha Wratten1, Linda Abetz-Webb2, Ethan Arenson2, Mike Greenwood2, Rebecca Hall3, Pip Griffiths4, Simon J Bowman5, Wolfgang Hueber6, Briana Ndife7, Daniel Kuessner6 and Pushpendra Goswami6, 1Adelphi Values, Macclesfield, United Kingdom, 2Adelphi Values, Bollington, United Kingdom, 3Adelphi Values Ltd, Bollington, United Kingdom, 4Former Adelphi Values, Bollington, United Kingdom, 5Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis, East Hanover, NJ

    Background/Purpose: Sjögren’s is a chronic autoimmune disease symptomatically characterized by dryness, pain and fatigue, which are typically assessed in clinical trials using EULAR Sjögren’s Syndrome…
  • Abstract Number: 0310 • ACR Convergence 2021

    Histopathology, Salivary Flow and Ultrasonography of the Parotid Gland: Three Complementary Measurements in Primary Sjögren’s Syndrome

    Martha S. van Ginkel1, Esther Mossel2, Erlin A. Haacke2, Suzanne Arends3, Silvia Liefers1, Konstantina Delli1, Jolien F. van Nimwegen4, Alja J. Stel5, Fred Spijkervet1, Arjan Vissink6, Bert van der vegt1, Frans Kroese3 and Hendrika Bootsma3, 1University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2University of Groningen, University Medical Center Groningen, Groningen, 3University Medical Center Groningen, Groningen, Netherlands, 4Univeristy of Groningen, University Medical Center Groningen, Groningen, Netherlands, 5University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, 6University of Groningen, University Medical Center Groningen, Leek, Netherlands

    Background/Purpose: Primary Sjögren’s syndrome is a systemic autoimmune disease characterized by dryness of the mouth and eyes. The impact of the disease on salivary glands…
  • Abstract Number: 0291 • ACR Convergence 2021

    IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality

    Scott Matson1, Candace Cephers2, Timothy Wilson3, Valerie Minarchick3, Kevin Brown4, Joshua Solomon4 and Kristen Demoruelle5, 1University of Kansas, Kansas City, MO, 2St Joseph Hospital, Internal Medicine, Denver, CO, 3University of Colorado, Denver, CO, 4National Jewish Health, Denver, CO, 5University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung disease (ILD) that shares many clinical features with rheumatoid arthritis (RA) associated ILD. Our…
  • Abstract Number: 0262 • ACR Convergence 2021

    High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients

    Clément TRIAILLE1, Cécile BOULANGER2, Tatiana SOKOLOVA1, Laurent MERIC de BELLEFON3, Adrien NZEUSSEU TOUKAP4, Christine GALANT5, Nisha LIMAYE6, Bernard LAUWERYS7 and Patrick DUREZ8, 1Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 2Service d’Hématologie, Oncologie et Rhumatologie pédiatrique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 3Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium, 5Service d’Anatomie Pathologique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 6Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université catholique de Louvain, Brussels, Belgium, 7UCB Pharma, Brussels, Belgium, 8Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium

    Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about…
  • Abstract Number: 0199 • ACR Convergence 2021

    Rapid Improvement in Cystoid Macular Edema with High Dose Intravenous Methylprednisolone in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases

    Nuria Vegas-Revenga1, José Luis Martin-Varillas2, Vanesa Calvo-Río3, Iñigo Gonzalez-Mazon4, Lara Sánchez-Bilbao5, Emma Beltrán Catalán6, Alejandro Fonollosa7, Ana Blanco8, Ana Blanco9, Miguel Cordero Coma10, Norberto Ortego11, Ignacio Torre12, Felix Hernandez13, Santiago Muñóz-Fernández14, Maria del Mar Esteban-Ortega14, Manuel Diaz-Llopis15, Joaquin Cañal5, Juan Antonio Ventosa5, Rosalía Demetrio-Pablo16, Lucia Cristina Dominguez Casas17, Santos Castañeda18, Iván Ferraz-Amaro19, Miguel Ángel gonzalez-Gay20 and Ricardo Blanco3, 1Hospital Galdakao, Galdakao, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4H. U. Marques de Valdecilla, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Hospital del Mar, Barcelona, Spain, 7Hospital Universitario de Cruces, Barakaldo, Spain, 8Hospital Universitario de Donostia, San Sebastián, 9Hospital Universitario de Donostia, Donostia, Spain, 10Hospital de León, Leon, Spain, 11Medicine Department, Universidad de Granada, Granada, Spain, 12Hospital Universitario de Basurto, Bilbao, Spain, 13Hospital Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain, 14Hospital Universitario Infanta Sofia, Madrid, Spain, 15Hospital Universitario La Fe, Valencia, Spain, 16Hospital Universitario de Marqués de Valdecilla, Santander, Spain, 17Hospital Universtario San Agustin, Oviedo, Spain, 18Hospital Universitario de la Princesa, Madrid, Spain, 19Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 20Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Cystoid Macular Edema (CME) is the most important cause of blindness in non-infectious uveitis (NIU) (1). Corticosteroids and conventional and/or biological immunosuppressant may be…
  • « Previous Page
  • 1
  • …
  • 571
  • 572
  • 573
  • 574
  • 575
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology